(Q37143139)

18 August 2017

1 reference

title

Natural killer cell-directed therapies: moving from unexpected results to successful strategies (English)

1 reference

18 August 2017

4

Nathalie Chaput

0 references

Laurence Zitvogel

series ordinal

5

object named as

Laurence Zitvogel

0 references

Magali Terme

series ordinal

1

object named as

Magali Terme

1 reference

18 August 2017

Evelyn Ullrich

2

0 references

author name string

Nicolas F Delahaye

series ordinal

3

1 reference

PubMed ID

18425105

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

5

1 reference

18 August 2017

486-494

1 reference

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells

18 August 2017

1 reference

7 January 2021

Regulation of immune responses through inhibitory receptors

1 reference

7 January 2021

Natural killer cells in human health and disease

1 reference

7 January 2021

Unravelling natural killer cell function: triggering and inhibitory human NK receptors

1 reference

7 January 2021

Ligands for natural killer cell receptors: redundancy or specificity

1 reference

7 January 2021

Functional subsets of mouse natural killer cells

1 reference

7 January 2021

Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46

1 reference

7 January 2021

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

1 reference

7 January 2021

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

1 reference

7 January 2021

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

1 reference

7 January 2021

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions

1 reference

7 January 2021

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

1 reference

7 January 2021

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

1 reference

7 January 2021

NKG2D function protects the host from tumor initiation

1 reference

7 January 2021

Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma

1 reference

7 January 2021

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

1 reference

7 January 2021

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

1 reference

7 January 2021

Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance

1 reference

7 January 2021

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

1 reference

7 January 2021

Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines.

1 reference

7 January 2021

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

1 reference

7 January 2021

Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci

1 reference

7 January 2021

Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection

1 reference

7 January 2021

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

7 January 2021

The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression

1 reference

7 January 2021

Human natural killer cell deficiencies

1 reference

7 January 2021

Human natural killer cell deficiencies and susceptibility to infection

1 reference

7 January 2021

The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense

1 reference

7 January 2021

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS

1 reference

7 January 2021

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

1 reference

7 January 2021

Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.

1 reference

7 January 2021

Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success

1 reference

7 January 2021

Decidual NK cells regulate key developmental processes at the human fetal-maternal interface.

1 reference

7 January 2021

Autoreactive T Cells Mediate NK Cell Degeneration in Autoimmune Disease

1 reference

7 January 2021

Autoimmunity mediated by innate immune effector cells

1 reference

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

7 January 2021

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles

1 reference

7 January 2021

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

7 January 2021

Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer

1 reference

7 January 2021

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.

1 reference

7 January 2021

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

1 reference

7 January 2021

Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells

1 reference

7 January 2021

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer

1 reference

7 January 2021

Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins

1 reference

7 January 2021

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

7 January 2021

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

1 reference

7 January 2021

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

1 reference

7 January 2021

Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor

1 reference

7 January 2021

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

1 reference

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

7 January 2021

KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation

1 reference

7 January 2021

Use of natural killer cells in hematopoetic stem cell transplantation

1 reference

7 January 2021

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation

1 reference

7 January 2021

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1 reference

7 January 2021

Association analyses of NCR3 polymorphisms with P. falciparum mild malaria

1 reference

7 January 2021

Prospects for the use of NK cells in immunotherapy of human cancer.

1 reference

7 January 2021

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

1 reference

7 January 2021

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

7 January 2021

First-in-class cancer therapeutic to stimulate natural killer cells

1 reference

7 January 2021

Potent antibody therapeutics by design

1 reference

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

7 January 2021

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

7 January 2021

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

7 January 2021

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format

1 reference

7 January 2021

Nature's TRAIL--on a path to cancer immunotherapy

1 reference

7 January 2021

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts

1 reference

7 January 2021

A novel dendritic cell subset involved in tumor immunosurveillance

1 reference

7 January 2021

CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells

1 reference

7 January 2021

Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells

1 reference

7 January 2021

Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells

1 reference

7 January 2021

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity

1 reference

7 January 2021

Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC).

1 reference

7 January 2021

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

1 reference

7 January 2021

NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity

1 reference

7 January 2021

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

1 reference

7 January 2021

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

1 reference

7 January 2021

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

1 reference

7 January 2021

Dendritic cell derived-exosomes: biology and clinical implementations

1 reference

7 January 2021

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

1 reference

7 January 2021

CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells

1 reference

7 January 2021

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

7 January 2021

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

1 reference

7 January 2021

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

1 reference

7 January 2021

Natural killer cells and natural killer cell activity in chronic fatigue syndrome

1 reference

7 January 2021

NK cells are essential for effective BCG immunotherapy

1 reference

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

7 January 2021

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

7 January 2021

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

7 January 2021

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer

1 reference

7 January 2021

A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer

1 reference

7 January 2021

Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome

1 reference

7 January 2021

Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors

1 reference

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

7 January 2021

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

7 January 2021

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

1 reference

7 January 2021

Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon

1 reference

7 January 2021

Immunological effects of interferon-alpha on chronic myelogenous leukemia.

1 reference

7 January 2021

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

1 reference

7 January 2021

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer

1 reference

7 January 2021

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

1 reference

7 January 2021

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function

1 reference

7 January 2021

Natural Killer andNK-LikeT-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96

1 reference

7 January 2021

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

1 reference

7 January 2021

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

1 reference

7 January 2021

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

1 reference

7 January 2021

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

1 reference

7 January 2021

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

1 reference

7 January 2021

Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody

1 reference

7 January 2021

Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis

1 reference

7 January 2021

Identifiers

DOI

10.1038/NI1580

1 reference

18 August 2017

1 reference

PubMed ID

18425105